Quality Over Quantity: Specific CAR T Cell Subgroup May Predict Low-Dose Therapy Success
核心洞察
Researchers identified a distinct subgroup of highly functional CAR T cells (搜索) whose abundance correlates directly with the success of low-dose CAR T-cell therapy.
The absolute number of these specific cells could serve as a future biomarker for predicting treatment response, even when overall cell counts are low.
The state of a patient's immune system before cell manufacturing begins also influences whether effective CAR T-cell products can be generated.
A collaborative research team from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (搜索) (BIH) has identified a specific subgroup of CAR T cells (搜索) that plays a key role in determining the success of low-dose CAR T-cell therapies. The findings, published in Nature Communications, address a long-standing clinical puzzle: why very low CAR T cell doses prove effective in some patients while others derive no benefit from treatment.
CAR T-cell therapies are used to treat certain advanced blood and lymphatic cancers when other treatments, such as chemotherapy or radiation therapy, have failed or after disease relapse. In this approach, a patient's own immune cells are genetically modified in the laboratory to recognize a specific target structure on the surface of cancer cells and selectively attack and destroy them. In many patients, cancer remains undetectable for extended periods following treatment. However, the manufacturing and expansion of these therapeutic immune cells is complex and time-consuming, and it is not always possible to produce the intended, ideally large number of cells required for treatment.
Highly Functional CAR T Cells Determine Treatment Success
The study is based on data and samples from the HD-CAR-1 trial, conducted by researchers from the Heidelberg Faculty of Medicine, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT). The scientists analyzed both original blood samples from patients with hematological malignancies (搜索) and the CAR T-cell products generated from those samples. Using high-resolution single-cell analyses, they examined the composition of CAR T-cell products administered at different dose levels, identifying the immune cell types they contained and assessing their functional activity. These findings were then compared between patients who responded to treatment and those who did not.
The researchers identified a subgroup of CAR T cells (搜索) whose abundance was directly associated with the success of low-dose therapies. These cells are characterized by a molecular profile that makes them particularly effective at killing tumor cells, as well as by the absence of two specific surface markers that can be used to identify them.
"The greater the number of these specific CAR T cells (搜索), the more effective the therapy was, even when the overall number of cells was relatively low," said Michael Schmitt, MD, Professor of Cellular Immunotherapy at Heidelberg Faculty of Medicine, Heidelberg University, Head of the Cell and Immunotherapy Research Program within the Department of Hematology, Oncology and Rheumatology at Heidelberg University Hospital, and one of the study's two senior authors. "Our findings suggest that the absolute number of these highly functional cells could serve as a biomarker for predicting the success of low-dose CAR T-cell therapy."
The Patient's Immune State Before Manufacturing Matters
The study also demonstrated that treatment success does not depend solely on the CAR T cells (搜索) themselves. "Equally important is the state of a patient's immune system before cell manufacturing begins," added Professor Simon Haas, co-senior author of the study, who conducts research at the Center of Genomic Medicine of the Berlin Institute of Health at Charité (搜索), the Max Delbrück Center for Molecular Medicine in Berlin, and Queen Mary University of London.
"Patients whose blood contained larger numbers of functional immune cells were more likely to yield effective CAR T-cell products," Professor Haas explained. By contrast, when the original blood samples contained a high proportion of cells that suppress immune responses, fewer highly functional CAR T cells (搜索) were generated, and patients were less likely to respond to treatment.
"Our analyses show that indicators of how well the final CAR T-cell product will perform can already be detected in the patient's blood before manufacturing begins," summarized Schayan Yousefian, a doctoral researcher in Professor Haas's group and first author of the study.
New Opportunities for Personalized CAR T-Cell Therapies
According to the study authors, the findings represent an important step toward further personalization of cancer immunotherapies. "Further research is needed to better understand the underlying mechanisms, validate the biomarker, and ultimately integrate it into routine clinical practice," said Professor Schmitt. One of the key next steps will be to determine the minimum number of highly functional CAR T cells (搜索) required for a therapy to have a reasonable likelihood of success.
Professor Haas noted that the findings also carry implications for healthcare policy and economics. CAR T-cell therapies can cost several hundred thousand euros per patient. "If our findings are confirmed in further studies, CAR T-cell manufacturing could become much more targeted in the future. This would benefit not only patients but also help conserve healthcare resources."